Annual CFO
-$160.60 M
-$26.93 M-20.14%
December 31, 2023
Summary
- As of February 12, 2025, SNDX annual cash flow from operations is -$160.60 million, with the most recent change of -$26.93 million (-20.14%) on December 31, 2023.
- During the last 3 years, SNDX annual CFO has fallen by -$89.34 million (-125.37%).
- SNDX annual CFO is now -651.31% below its all-time high of $29.13 million, reached on December 31, 2021.
Performance
SNDX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$62.32 M
+$9.32 M+13.01%
September 30, 2024
Summary
- As of February 12, 2025, SNDX quarterly cash flow from operations is -$62.32 million, with the most recent change of +$9.32 million (+13.01%) on September 30, 2024.
- Over the past year, SNDX quarterly CFO has dropped by -$17.67 million (-39.57%).
- SNDX quarterly CFO is now -161.88% below its all-time high of $100.71 million, reached on December 31, 2021.
Performance
SNDX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$258.86 M
-$17.67 M-7.33%
September 30, 2024
Summary
- As of February 12, 2025, SNDX TTM cash flow from operations is -$258.86 million, with the most recent change of -$17.67 million (-7.33%) on September 30, 2024.
- Over the past year, SNDX TTM CFO has dropped by -$116.72 million (-82.11%).
- SNDX TTM CFO is now -988.62% below its all-time high of $29.13 million, reached on December 31, 2021.
Performance
SNDX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
SNDX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.1% | -39.6% | -82.1% |
| 3 y3 years | -125.4% | -48.6% | -2744.4% |
| 5 y5 years | -134.3% | -48.6% | -2744.4% |
SNDX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -651.3% | at low | -161.9% | +25.4% | -988.6% | at low |
| 5 y | 5-year | -651.3% | at low | -161.9% | +25.4% | -988.6% | at low |
| alltime | all time | -651.3% | at low | -161.9% | +25.4% | -988.6% | at low |
Syndax Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$62.32 M(-13.0%) | -$258.86 M(+7.3%) |
| Jun 2024 | - | -$71.64 M(-14.2%) | -$241.19 M(+17.7%) |
| Mar 2024 | - | -$83.55 M(+102.1%) | -$204.92 M(+27.6%) |
| Dec 2023 | -$160.60 M(+20.1%) | -$41.35 M(-7.4%) | -$160.60 M(+13.0%) |
| Sep 2023 | - | -$44.65 M(+26.2%) | -$142.15 M(+12.8%) |
| Jun 2023 | - | -$35.37 M(-9.8%) | -$126.04 M(-3.8%) |
| Mar 2023 | - | -$39.23 M(+71.3%) | -$130.97 M(-2.0%) |
| Dec 2022 | -$133.68 M(-558.9%) | -$22.89 M(-19.8%) | -$133.68 M(+1227.2%) |
| Sep 2022 | - | -$28.54 M(-29.2%) | -$10.07 M(+55.6%) |
| Jun 2022 | - | -$40.31 M(-3.9%) | -$6.47 M(-166.1%) |
| Mar 2022 | - | -$41.93 M(-141.6%) | $9.79 M(-66.4%) |
| Dec 2021 | $29.13 M(-140.9%) | $100.71 M(-503.7%) | $29.13 M(-133.4%) |
| Sep 2021 | - | -$24.94 M(+3.7%) | -$87.21 M(+8.3%) |
| Jun 2021 | - | -$24.05 M(+6.4%) | -$80.56 M(+3.4%) |
| Mar 2021 | - | -$22.59 M(+44.5%) | -$77.92 M(+9.4%) |
| Dec 2020 | -$71.26 M(+40.8%) | -$15.63 M(-14.6%) | -$71.26 M(+4.2%) |
| Sep 2020 | - | -$18.30 M(-14.5%) | -$68.36 M(+16.7%) |
| Jun 2020 | - | -$21.41 M(+34.4%) | -$58.59 M(+17.9%) |
| Mar 2020 | - | -$15.93 M(+25.1%) | -$49.71 M(-1.8%) |
| Dec 2019 | -$50.61 M(-26.1%) | -$12.73 M(+49.2%) | -$50.61 M(-4.4%) |
| Sep 2019 | - | -$8.53 M(-31.9%) | -$52.93 M(-15.8%) |
| Jun 2019 | - | -$12.53 M(-25.6%) | -$62.87 M(-4.0%) |
| Mar 2019 | - | -$16.83 M(+11.9%) | -$65.49 M(-4.4%) |
| Dec 2018 | -$68.53 M | -$15.04 M(-18.6%) | -$68.53 M(+3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$18.47 M(+21.9%) | -$66.21 M(+14.3%) |
| Jun 2018 | - | -$15.15 M(-23.8%) | -$57.92 M(+6.1%) |
| Mar 2018 | - | -$19.87 M(+56.2%) | -$54.57 M(+15.2%) |
| Dec 2017 | -$47.37 M(+34.7%) | -$12.72 M(+25.0%) | -$47.37 M(+5.1%) |
| Sep 2017 | - | -$10.18 M(-13.7%) | -$45.06 M(-2.7%) |
| Jun 2017 | - | -$11.80 M(-6.9%) | -$46.33 M(+11.9%) |
| Mar 2017 | - | -$12.67 M(+21.6%) | -$41.42 M(+17.8%) |
| Dec 2016 | -$35.16 M(+1348.0%) | -$10.42 M(-9.0%) | -$35.16 M(+21.1%) |
| Sep 2016 | - | -$11.45 M(+66.2%) | -$29.04 M(+27.5%) |
| Jun 2016 | - | -$6.89 M(+7.6%) | -$22.77 M(+14.6%) |
| Mar 2016 | - | -$6.40 M(+49.1%) | -$19.88 M(+718.6%) |
| Dec 2015 | -$2.43 M(-83.1%) | -$4.29 M(-17.1%) | -$2.43 M(+51.0%) |
| Sep 2015 | - | -$5.18 M(+29.7%) | -$1.61 M(-265.4%) |
| Jun 2015 | - | -$4.00 M(-136.2%) | $972.00 K(-16.5%) |
| Mar 2015 | - | $11.04 M(-417.8%) | $1.16 M(-108.1%) |
| Dec 2014 | -$14.39 M(+97.3%) | -$3.48 M(+33.6%) | -$14.39 M(+5.3%) |
| Sep 2014 | - | -$2.60 M(-31.6%) | -$13.67 M(+3.6%) |
| Jun 2014 | - | -$3.80 M(-15.7%) | -$13.20 M(+27.9%) |
| Mar 2014 | - | -$4.51 M(+63.7%) | -$10.32 M(+41.5%) |
| Dec 2013 | -$7.29 M(-21.4%) | -$2.76 M(+29.6%) | -$7.29 M(+60.7%) |
| Sep 2013 | - | -$2.13 M(+129.4%) | -$4.54 M(+88.2%) |
| Jun 2013 | - | -$927.00 K(-37.6%) | -$2.41 M(+62.4%) |
| Mar 2013 | - | -$1.49 M | -$1.49 M |
| Dec 2012 | -$9.28 M | - | - |
FAQ
- What is Syndax Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals annual CFO year-on-year change?
- What is Syndax Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly CFO year-on-year change?
- What is Syndax Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals TTM CFO year-on-year change?
What is Syndax Pharmaceuticals annual cash flow from operations?
The current annual CFO of SNDX is -$160.60 M
What is the all time high annual CFO for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high annual cash flow from operations is $29.13 M
What is Syndax Pharmaceuticals annual CFO year-on-year change?
Over the past year, SNDX annual cash flow from operations has changed by -$26.93 M (-20.14%)
What is Syndax Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of SNDX is -$62.32 M
What is the all time high quarterly CFO for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high quarterly cash flow from operations is $100.71 M
What is Syndax Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, SNDX quarterly cash flow from operations has changed by -$17.67 M (-39.57%)
What is Syndax Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of SNDX is -$258.86 M
What is the all time high TTM CFO for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high TTM cash flow from operations is $29.13 M
What is Syndax Pharmaceuticals TTM CFO year-on-year change?
Over the past year, SNDX TTM cash flow from operations has changed by -$116.72 M (-82.11%)